摘要
目的 观察前列腺素E2（PGE1）对糖尿病肾病（DN）患者尿微量白蛋白及肾功能近期疗效。方法 选择早期DN患者83例．随机分为两组。观察组42例，在原来治疗基础上给予LipoPGE1（前列腺素E1脂微球）10μg加入生理盐水20ml静脉注射，每天1次．连续3周；对照组41例，进入试验后维持原治疗不变．其降糖、降压、调脂等治疗情况与观察组基本一致。两组患者人组前调整降压药和降糖药，使血压维持在110—135／70～85mmHg，空腹血糖维持在4．0～7．0mmol／1．并稳定2周进入试验。所有患者在治疗前、治疗3周结束和治疗后12周时均检测尿微量白蛋白排泄率（UAE）、血糖（FBG）、血尿素氮（BUN）、血肌酐（Scr）、糖化血红蛋白（HbAlc）等。结果 应用LipoPGE，治疗3周时就能明显降低早期DN患者的尿微量白蛋白．逆转异常的肾功能，而且此作用在停药12周后仍然很明显，对照组则无此变化。结论 LipoPGE1是治疗早期DN起效迅速、安全且作用较持久的药物。
Objective To evaluate the short-term therapeutic effect of Lipo PGE1 used in patients with early stage of diabetic nephropathy by measurement of the UAE and renal function. Methods 83 cases with early stage of diabetic nephropathy were randomly grouped into two separated group. In Lipo PGE1 group, the 42 cases received the usage of 10μg Lipo PGE1 mixed in the 20ml NS i.v. drip qd for 3 weeks besides other regular treatment. In control group, the cases received almost the same as treatment of the Lipo PGE1 group, except the Lipo PGE1. The patients＂ blood pressure within 110- 135/70- 85mmHg and FBG within 4.0- 7.0mmol/L should be maintained for 3 weeks before entering into the study. The measurements of UAG,FBG, BUN, Scr and HbAlc were assigned to take before the study,3 weeks and 12 weeks after the ending of the study. Results Using Lipo PGE1 for 3 weeks could obviously reduce UAG and reverse abnormal renal function of patients with early stage of DN. And the effect of the Lipo PGE1 was still obvious at the 12 weeks after the last using of the drug, and the control group had no such changing. Conclusion Lipo PGE1 is a rapid-effective.safe and long-functional drug to treat early stage of DN.
出处
《中国基层医药》
CAS
2007年第6期925-926,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
糖尿病肾病
前列地尔
白蛋白尿
肾功能试验
Diabetic nephropathies
Alprostadil
Albuminuria
Kidney function tests
